[go: up one dir, main page]

MA32803B1 - Utilisation de 7-chloro-n,n,5-triméthyl-4-oxo-3-phényl-3,5-dihydro-4h- pyridazino[4,5-b]indole-1-acétamide en tant que marqueur biologique de niveaux de récepteur périphérique des benzodiazépine - Google Patents

Utilisation de 7-chloro-n,n,5-triméthyl-4-oxo-3-phényl-3,5-dihydro-4h- pyridazino[4,5-b]indole-1-acétamide en tant que marqueur biologique de niveaux de récepteur périphérique des benzodiazépine

Info

Publication number
MA32803B1
MA32803B1 MA33858A MA33858A MA32803B1 MA 32803 B1 MA32803 B1 MA 32803B1 MA 33858 A MA33858 A MA 33858A MA 33858 A MA33858 A MA 33858A MA 32803 B1 MA32803 B1 MA 32803B1
Authority
MA
Morocco
Prior art keywords
pyridazino
benzodiazepine
acetamide
indole
dihydro
Prior art date
Application number
MA33858A
Other languages
Arabic (ar)
English (en)
Inventor
Jesus Benavides
Hervé Boutin
Marie-Noëlle Castel
Annelaure Damont
Frédéric Dolle
Philippe Hantraye
Frank Marguet
Thomas Rooney
Luc Rivron
Bertrand Tavitian
Cyrille Thominiaux
Original Assignee
Commissariat Energie Atomique
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Commissariat Energie Atomique, Sanofi Aventis filed Critical Commissariat Energie Atomique
Publication of MA32803B1 publication Critical patent/MA32803B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/52—Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne l'utilisation d'une forme radiomarquée de 7-chloro-N,N,5-triméthyl-4-oxo-3-phényl-3,5-dihydro-4H- pyridazino[4,5-b]indole-1-acétamide comme marqueur biologique pour la détection, chez un individu, de niveaux de RPB associés à des états normaux et pathologiques. Elle concerne également un procédé de détection de niveaux de RPB associés à des états normaux et pathologiques et un nécessaire de diagnostic.
MA33858A 2008-10-28 2011-05-19 Utilisation de 7-chloro-n,n,5-triméthyl-4-oxo-3-phényl-3,5-dihydro-4h- pyridazino[4,5-b]indole-1-acétamide en tant que marqueur biologique de niveaux de récepteur périphérique des benzodiazépine MA32803B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08291013A EP2181717A1 (fr) 2008-10-28 2008-10-28 Utilisation du 7-chloro-N,N,5-triméthyl-4-oxo-3-phényl-3,5-dihydro-4H-pyridazino[4,5-B]indole-1-acétamide en tant que biomarqueur de niveaux de récepteur de la benzodiazépine
PCT/IB2009/007562 WO2010049819A1 (fr) 2008-10-28 2009-10-27 Utilisation de 7-chloro-n,n,5-triméthyl-4-oxo-3-phényl-3,5-dihydro-4h- pyridazino[4,5-b]indole-1-acétamide en tant que marqueur biologique de niveaux de récepteurs périphériques des benzodiazépines

Publications (1)

Publication Number Publication Date
MA32803B1 true MA32803B1 (fr) 2011-11-01

Family

ID=40262247

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33858A MA32803B1 (fr) 2008-10-28 2011-05-19 Utilisation de 7-chloro-n,n,5-triméthyl-4-oxo-3-phényl-3,5-dihydro-4h- pyridazino[4,5-b]indole-1-acétamide en tant que marqueur biologique de niveaux de récepteur périphérique des benzodiazépine

Country Status (32)

Country Link
US (2) US20120039816A1 (fr)
EP (2) EP2181717A1 (fr)
JP (1) JP5743894B2 (fr)
KR (2) KR20110098711A (fr)
CN (1) CN102223899B (fr)
AR (1) AR073983A1 (fr)
AU (1) AU2009309339C1 (fr)
BR (1) BRPI0920412A2 (fr)
CA (1) CA2741620C (fr)
CL (2) CL2011000954A1 (fr)
CO (1) CO6382141A2 (fr)
CY (1) CY1115211T1 (fr)
DK (1) DK2349352T3 (fr)
EA (1) EA020612B1 (fr)
ES (1) ES2452665T3 (fr)
HK (1) HK1161686A1 (fr)
HR (1) HRP20140250T1 (fr)
IL (1) IL212473A (fr)
MA (1) MA32803B1 (fr)
ME (2) ME01819B (fr)
MX (1) MX2011004420A (fr)
MY (1) MY152968A (fr)
NZ (1) NZ592479A (fr)
PL (1) PL2349352T3 (fr)
PT (1) PT2349352E (fr)
RS (1) RS53273B (fr)
SI (1) SI2349352T1 (fr)
SM (1) SMT201400070B (fr)
TW (1) TWI450728B (fr)
UY (1) UY32206A (fr)
WO (1) WO2010049819A1 (fr)
ZA (1) ZA201103082B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201016038D0 (en) * 2010-09-24 2010-11-10 Ge Healthcare Ltd In vivo imaging method
GB201016411D0 (en) 2010-09-30 2010-11-10 Ge Healthcare Ltd In vivo imaging method for cancer
EP4278367A1 (fr) * 2021-01-15 2023-11-22 Minnetronix Neuro, Inc. Systèmes et procédés de gestion, de surveillance et de traitement d'affections de patients

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2766823B1 (fr) 1997-07-30 1999-10-08 Synthelabo Derives de 4-oxo-3,5-dihydro-4h-pyridazino[4,5-b] indole-1-acetamide, leur preparation et leur application en therapeutique
FR2788696B1 (fr) 1999-01-26 2004-03-05 Synthelabo Utilisation de derives de pyridazino [4,5-b] indole-1-acetamide pour la preparation de medicaments destines aux maladies du systeme nerveux central
JP4362457B2 (ja) * 2005-04-26 2009-11-11 独立行政法人科学技術振興機構 神経因性疼痛治療剤
BRPI0716583A2 (pt) * 2006-08-24 2013-10-01 Australian Nuclear Science Tec ligandos fluorados para marcar recptores de benzodiazepina perifÉricos
CA2680762A1 (fr) * 2007-03-12 2008-09-25 National Institute Of Radiological Sciences Visualisation par tomographie par emission de positons d'une neuro-inflammation associee aux amyloides dans le cerveau
EP1997515A1 (fr) * 2007-05-30 2008-12-03 Bayer Schering Pharma Aktiengesellschaft Utilisation de dérivés radiomarqués phenyloxyaniline pour la préparation de compositions pour imager des maladies associées à l'activation du récepteur pheriphérique benzodiazépine

Also Published As

Publication number Publication date
IL212473A0 (en) 2011-06-30
AR073983A1 (es) 2010-12-15
KR20110098711A (ko) 2011-09-01
AU2009309339C1 (en) 2016-01-14
RS53273B (en) 2014-08-29
BRPI0920412A2 (pt) 2015-12-22
SI2349352T1 (sl) 2014-07-31
MX2011004420A (es) 2011-11-18
US20170160287A1 (en) 2017-06-08
EP2181717A1 (fr) 2010-05-05
NZ592479A (en) 2013-03-28
TW201029671A (en) 2010-08-16
ME01128B (me) 2013-03-20
CN102223899A (zh) 2011-10-19
EA020612B1 (ru) 2014-12-30
IL212473A (en) 2015-01-29
CA2741620C (fr) 2016-08-16
CN102223899B (zh) 2014-08-27
AU2009309339A1 (en) 2010-05-06
UY32206A (es) 2010-05-31
CL2013001041A1 (es) 2014-01-24
EA201170613A1 (ru) 2011-12-30
CO6382141A2 (es) 2012-02-15
EP2349352A1 (fr) 2011-08-03
AU2009309339B2 (en) 2015-08-27
ES2452665T3 (es) 2014-04-02
WO2010049819A8 (fr) 2011-05-26
US20120039816A1 (en) 2012-02-16
KR20160070846A (ko) 2016-06-20
DK2349352T3 (da) 2014-03-31
EP2349352B1 (fr) 2013-12-25
MY152968A (en) 2014-12-15
ZA201103082B (en) 2013-01-30
WO2010049819A1 (fr) 2010-05-06
JP2012507031A (ja) 2012-03-22
JP5743894B2 (ja) 2015-07-01
SMT201400070B (it) 2014-07-07
CL2011000954A1 (es) 2012-01-20
PL2349352T3 (pl) 2014-05-30
HK1161686A1 (en) 2012-08-03
PT2349352E (pt) 2014-04-03
CY1115211T1 (el) 2017-01-04
ME01819B (me) 2014-09-20
TWI450728B (zh) 2014-09-01
CA2741620A1 (fr) 2010-05-06
HRP20140250T1 (hr) 2014-06-20

Similar Documents

Publication Publication Date Title
HN2005000795A (es) Pirimidinas como antagonistas del receptor de prostaglandina d2
MA33208B1 (fr) Anticorps anti-fgfr3 et procédés d'utilisation de ceux-ci
ECSP099619A (es) Anticuerpos anti-robo4 y sus usos
CO6321189A2 (es) Compuestos de tiazol y oxazol de bencen-sulfonamida
NI201000055A (es) 2' - fluoro - 2' - desoxitetrahidrouridinas como inhibidores de citidina desaminasa.
CR20150586A (es) Compuestos triciclicos que contienen nitrogeno como agentes antibactercianos
ATE496051T1 (de) Pyrazolotetrahydropyridinderivate als orexinrezeptorantagonisten
HN2008000179A (es) Compuestos triciclicos,composiciones y procedimientos
CL2012000033A1 (es) Compuestos n-(3-(4as,7as)-2-amino-4a,5,7,7a-tetrahidro-4h-furo[3,4-d][1,3] tiazin-7a-il)-4- fluorofenilo) -5-fluoropiconilamida, inhibidor de bace; composicion farmaceutica que los comprende, uso del compuesto para el tratamiento de la enfermedad de alzheimer.
NI201000005A (es) Agentes citotóxicos que comprenden nuevos derivados de tomaimicina y su uso terapéutico.
UY32276A (es) Derivados de n-{[1s,4s,6s)-3-(2-piridinilcarbonil)-3-azabiciclo[4.1.0]hept-4-il}metil}-2heteroarilamina y uso de los mismos
MA33198B1 (fr) Anticorps anti-her di-spécifiques
UY31690A (es) Compuestos pesticidas de arilo de anillo condensado
ECSP088972A (es) Isoindoles sustituidos como inhibidores de bace y su uso
SV2008003074A (es) Piridin[3,4-b] pirazinonas
CL2011002255A1 (es) Compuestos derivados de 2-acetamino-5-aril-(1,2,4-triazolona o imidazolona), antagonista del receptor v1a y v2; composicion farmaceutica que los comprende; procedimiento de preparacion; y su uso en el tratamiento de insuficiencia cardiaca, hiponatremia hipervolemica y euvolemica, ascitis, ademas, entre otras.
HN2008001530A (es) Compuestos de amino pirimidina 2,6- sustituidos -4-monosustituidos como antagonistas del receptor de prostaglandina d2
CR11861A (es) Compuestos organicos
PA8671301A1 (es) Pirrolopiridinas sustituidas, composiciones que las contienen, proceso de fabricación y utilización
ECSP099760A (es) Compuestos 1,3-diona biciclicos herbicidamente activos
UY30572A1 (es) N-(1-ftalazin-1-il-piperidin-4-il)-amidas como moduladores del receptor ep2
CR10060A (es) 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas
HN2011000076A (es) Derivados de piridino-piridinonas, su preparacion.
EA201101116A1 (ru) Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина
ECSP088925A (es) Nitrilos espirocíclicos como inhibidores de proteasa